{"ATC Code":"V - Various","Abbreviation":"","Aliases":["Flumazepil","Mazicon","Flumazenilum","Flumazenilo","Ro-15-1788","Flumazil","Ro15-1788","RO-151788","Ro 15-1788/000","RO-1722"],"Biological Half-Life":"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).","CAS":"78755-81-4","ChEBI":"CHEBI:5103","ChEMBL":"CHEMBL407","ChemicalClasses":["benzodiazepine"],"Chirality":"achiral","Classes":null,"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Antidotes; GABA Modulators; Benzodiazepines","Drug Indication":"For the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, and where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures. Also for the management of benzodiazepine overdose as an adjunct for appropriate supportive and symptomatic measures.","DrugClasses":["opioid"],"EliminationHalfLife":"7–15 min (initial)  20–30 min (brain)  40–80 min (terminal)","European Community (EC) Number":"616-650-9","FDA Pharmacological Classification":"40P7XK9392","HMDB ID":"HMDB0015336","HeavyAtomCount":22,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Antidotes; GABA Modulators; Benzodiazepines","IUPACName":"ethyl 8-fluoro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate","Impurities":["flumazenil dione","dimethylformamide diethylacetal","desfluoro flumazenil","desfluoro hydroxyflumazenil","flumazenil acid","chloroflumazenil"],"InChI":"InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3","InChIKey":"OFBIFZUFASYYRE-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)","Melting Point":"201-203 °C","MolecularFormula":"C\u003csub\u003e15\u003c/sub\u003eH\u003csub\u003e14\u003c/sub\u003eFN\u003csub\u003e3\u003c/sub\u003eO\u003csub\u003e3\u003c/sub\u003e","MolecularWeight":"303.29 g/mol","Pharmacodynamics":"Flumazenil antagonizes the CNS effects produced by benzodiazepines, but does not antagonize the central nervous system effects of drugs affecting GABA-ergic neurons by means other than the benzodiazepine receptor (including ethanol, barbiturates, or general anesthetics) and does not reverse the effects of opioids.","Physical Description":"Solid","PrevSalts":[],"PubChemId":3373,"Record Description":["Flumazenil is an organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose. It has a role as a GABA antagonist and an antidote to benzodiazepine poisoning. It is an ethyl ester, an organofluorine compound and an imidazobenzodiazepine.","Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system.","Flumazenil is a Benzodiazepine Antagonist.","Flumazenil is an imidazo-benzodiazepine derivative, effective in reversing benzodiazepine-induced activities. Flumazenil antagonizes the benzodiazepine binding site of the gamma-aminobutyric acid (GABA)/benzodiazepine receptor complex in the central nervous system (CNS), thereby preventing the chloride channel opening events and inhibiting neuronal hyperpolarization. As a result, flumazenil reverses benzodiazepine-induced effects including sedation, psychomotor deficits, amnesia, and hypoventilation in a dose-dependent manner.","FLUMAZENIL is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 investigational indications. This drug has a black box warning from the FDA.","A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.","Flumazenil is an organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose. It has a role as a GABA antagonist and an antidote to benzodiazepine poisoning. It is an ethyl ester, an organofluorine compound and an imidazobenzodiazepine."],"RefCount":4,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Flumazenil","Name":"Flumazenil","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q421920","Name":"Flumazenil","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB01205","Name":"Flumazenil","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3373","Name":"Flumazenil","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL407","Name":"Flumazenil","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5103","Name":"Flumazenil","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=78755-81-4","Name":"Flumazenil","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0015336","Name":"Flumazenil","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07825","Name":"Flumazenil","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/40P7XK9392","Name":"Flumazenil","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID2023064","Name":"Flumazenil","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 3373, Flumazenil. Accessed June 25, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/3373\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/3373\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Flumazenil. UNII: 40P7XK9392. Global Substance Registration System. Accessed June 25, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/40P7XK9392\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/40P7XK9392\u003c/a\u003e","Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed June 25, 2025. \u003ca href=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003ehttps://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003c/a\u003e"],"SMILES":"CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C","Scheduling":[{"gov":"Australia","ref":[],"schedule":"S4 substance"},{"gov":"Brazil","ref":["3"],"schedule":"C1 substance"},{"gov":"Canada","ref":[],"schedule":"prescription only substance"},{"gov":"United Kingdom","ref":[],"schedule":"prescription only substance"},{"gov":"United States","ref":[],"schedule":"prescription only substance"}],"Solubility":"1.04e+00 g/L","StoreUNII":["40P7XK9392"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="93.086mm" version="1.2" viewBox="0 0 120.474 93.086" width="120.474mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="94.0" stroke="none" width="121.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="119.449" x2="112.979" y1="1.026" y2="14.824"/>
                  
            <line class="bond" id="mol1bnd2" x1="112.979" x2="101.448" y1="14.824" y2="15.808"/>
                  
            <line class="bond" id="mol1bnd3" x1="96.114" x2="91.324" y1="19.702" y2="29.918"/>
                  
            <g class="bond" id="mol1bnd4">
                        
                <line x1="91.921" x2="98.785" y1="28.644" y2="38.49"/>
                        
                <line x1="89.921" x2="96.784" y1="30.038" y2="39.885"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="98.785" x2="95.35300000000001" y1="38.49" y2="33.567"/>
                <line class="hi" stroke="#FF0D0D" x1="96.784" x2="93.3525" y1="39.885" y2="34.9615"/>
            </g>
                  
            <line class="bond" id="mol1bnd5" x1="91.324" x2="76.139" y1="29.918" y2="31.214"/>
                  
            <g class="bond" id="mol1bnd6">
                        
                <line x1="68.26" x2="76.139" y1="44.259" y2="31.214"/>
                        
                <line x1="67.088" x2="73.135" y1="41.483" y2="31.471"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd7" x1="68.26" x2="74.864" y1="44.259" y2="57.975"/>
                  
            <line class="bond" id="mol1bnd8" x1="74.864" x2="70.047" y1="57.975" y2="67.98"/>
                  
            <line class="bond" id="mol1bnd9" x1="64.956" x2="53.426" y1="72.461" y2="75.146"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="54.747" x2="52.115" y1="74.838" y2="86.39"/>
                        
                <line x1="52.369" x2="49.738" y1="74.297" y2="85.848"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="52.115" x2="53.431" y1="86.39" y2="80.614"/>
                <line class="hi" stroke="#FF0D0D" x1="49.738" x2="51.0535" y1="85.848" y2="80.07249999999999"/>
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="53.426" x2="41.539" y1="75.146" y2="65.595"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="41.539" x2="41.539" y1="65.595" y2="50.355"/>
                        
                <line x1="39.101" x2="39.101" y1="64.187" y2="51.764"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="41.539" x2="50.394" y1="50.355" y2="43.241"/>
                  
            <line class="bond" id="mol1bnd14" x1="68.26" x2="56.731" y1="44.259" y2="41.575"/>
                  
            <line class="bond" id="mol1bnd15" x1="53.096" x2="52.122" y1="36.96" y2="25.621"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="62.932" x2="52.122" y1="21.056" y2="25.621"/>
                        
                <line x1="63.88" x2="54.703" y1="23.302" y2="27.178"/>
                      
                <line class="hi" stroke="#3050F8" x1="62.932" x2="57.527" y1="21.056" y2="23.3385"/>
                <line class="hi" stroke="#3050F8" x1="63.88" x2="59.2915" y1="23.302" y2="25.240000000000002"/>
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="76.139" x2="69.02" y1="31.214" y2="22.992"/>
                  
            <line class="bond" id="mol1bnd18" x1="41.539" x2="28.331" y1="50.355" y2="42.735"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="28.331" x2="15.123" y1="42.735" y2="50.355"/>
                        
                <line x1="28.331" x2="17.562" y1="45.551" y2="51.764"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="15.123" x2="15.123" y1="50.355" y2="65.595"/>
                  
            <g class="bond" id="mol1bnd21">
                        
                <line x1="15.123" x2="28.331" y1="65.595" y2="73.215"/>
                        
                <line x1="17.562" x2="28.331" y1="64.187" y2="70.4"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd22" x1="41.539" x2="28.331" y1="65.595" y2="73.215"/>
                  
            <line class="bond" id="mol1bnd23" x1="15.123" x2="4.442" y1="65.595" y2="71.765"/>
                  
            <line class="bond" id="mol1bnd24" x1="71.076" x2="77.789" y1="75.207" y2="83.585"/>
                  
            <path class="atom" d="M100.053 16.117q-.0 .756 -.256 1.327q-.256 .566 -.756 .882q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.888q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM96.189 16.117q.0 .923 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.393 .524 -.393 1.453z" id="mol1atm3" stroke="none"/>
                  
            <path class="atom" d="M102.298 42.418q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.245 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.733 -.0 1.233 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM98.434 42.418q.0 .922 .387 1.458q.393 .53 1.22 .53q.84 .0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" id="mol1atm5" stroke="none"/>
                  
            <path class="atom" d="M70.201 74.141h-.721l-2.619 -4.066h-.03q.012 .238 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" fill="#3050F8" id="mol1atm9" stroke="none"/>
                  
            <path class="atom" d="M52.3 90.002q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.309q.25 -.566 .756 -.882q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .876q.256 .565 .256 1.327zM48.437 90.002q-.0 .923 .387 1.459q.392 .529 1.22 .529q.839 .0 1.22 -.529q.387 -.536 .387 -1.459q.0 -.929 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.226 .524q-.393 .523 -.393 1.452z" id="mol1atm11" stroke="none"/>
                  
            <path class="atom" d="M55.367 43.255h-.72l-2.62 -4.066h-.029q.012 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.608 4.054h.029q-.006 -.107 -.018 -.327q-.011 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" fill="#3050F8" id="mol1atm14" stroke="none"/>
                  
            <path class="atom" d="M68.103 22.141h-.72l-2.62 -4.066h-.029q.011 .238 .029 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" id="mol1atm16" stroke="none"/>
                  
            <path class="atom" d="M1.173 75.667h-.613v-4.899h2.732v.542h-2.119v1.738h1.994v.542h-1.994v2.077z" fill="#90E050" id="mol1atm21" stroke="none"/>
                
            <line class="hi" id="mol1bnd2" stroke="#FF0D0D" x1="101.448" x2="107.2135" y1="15.808" y2="15.315999999999999"/>
            <line class="hi" id="mol1bnd3" stroke="#FF0D0D" x1="96.114" x2="93.719" y1="19.702" y2="24.810000000000002"/>
            <line class="hi" id="mol1bnd8" stroke="#3050F8" x1="70.047" x2="72.4555" y1="67.98" y2="62.977500000000006"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="64.956" x2="59.191" y1="72.461" y2="73.8035"/>
            <line class="hi" id="mol1bnd13" stroke="#3050F8" x1="50.394" x2="45.966499999999996" y1="43.241" y2="46.798"/>
            <line class="hi" id="mol1bnd14" stroke="#3050F8" x1="56.731" x2="62.49550000000001" y1="41.575" y2="42.917"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="53.096" x2="52.608999999999995" y1="36.96" y2="31.2905"/>
            <line class="hi" id="mol1bnd17" stroke="#3050F8" x1="69.02" x2="72.5795" y1="22.992" y2="27.103"/>
            <line class="hi" id="mol1bnd23" stroke="#90E050" x1="4.442" x2="9.782499999999999" y1="71.765" y2="68.68"/>
            <line class="hi" id="mol1bnd24" stroke="#3050F8" x1="71.076" x2="74.4325" y1="75.207" y2="79.39599999999999"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Title":"Flumazenil","UNII":"40P7XK9392","Wikidata":"Q421920","Wikipedia":"Flumazenil","XLogP":1}